Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Benzinga · 08/28/2025 13:12
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.